University of South Florida

Rgenix, Inc.

Padmini Kavuru

Eduardo J Martinez

Michael John Zaworotko

Roland Douglas Shytle

Aniruddh Singh

Tien Teng Ong

Andreas G Grill

Heather Clarke

Arora Kapildev

Twarita Pujari

Lissette Marshall

Adam John Smith

Nicholas D Paschalides

Ryan N Cantwell

Tranhha Nguyen

Stephen A Wald

Co-crystals comprising at least one nutraceutical compound and at least one co-crystal former with or without impurities. These co-crystals may be included in compositions (optionally also including other components such as pharmaceutically acceptable excipients, other nutritional supplements, etc.) having utility as pharmaceuticals, nutraceuticals, nutritional supplements, and foodstuffs.

Nutraceutical co-crystal compositions

The present invention relates to new pharmaceutical salts of &#x3b2;-GPA which exhibit improved physical properties. In particular, the invention relates to salts of &#x3b2;-GPA with improved flow properties (e.g., improved Carr's index and/or Hausner ratio) such as fumarate salts, succinate salts, and oxalate salts. The invention also relates to pharmaceutical compositions including a pharmaceutically effective amount of one or more salts of &#x3b2;-GPA, as well as methods of treating cancer including administration of a formulation including a &#x3b2;-GPA salt of the invention to a subject in need thereof.

Pharmaceutically acceptable salts of B-Guanidinopropionic acid with improved properties and uses thereof

2:1 cocrystals of amino acids and Li+ salts crystallize from hot water to afford water stable cationic networks based upon tetrahedral lithium cations: bilayered square grids, a lithium zeolitic metal-organic material (LiZMOM) and several lithium diamondoid metal-organic materials (LiDMOMs). The compositions may be used as a pharmaceutical for the treatment of suicidality and other disorders that require lithium to penetrate the blood brain barrier and exert therapeutic effects in the CNS. Advantageously, the novel cocrystal forms described herein may be used to lower the oral dose required to achieve therapeutic concentrations of lithium in the brain, thus reducing the peripheral toxicity and potentially broadening the therapeutic index in comparison to conventional lithium forms.

Lithium cocrystal compositions

Pharmaceutically acceptable salts of B-guanidinopropionic acid with improved properties and uses thereof

Growing community of inventors

Fitchburg, MA, United States of America

Padmini Kavuru